Exchange: OTC·Updated 03:44 PM EDT

BETRF News

News
all
press releases
A Non-Hallucinogenic LSD Derivative Just Attracted US$100 Million
Psychedelic drug development has increasingly focused on separating potential therapeutic effects from the hallucinogenic experience. One emerging approach preserves the molecular foundation of compounds such as LSD while removing the psychedelic effects, with researchers targeting neurological conditions for which many patients still lack adequate treatment options.Shares of BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) are climbing Thursday after the company closed a public offering of common shares and pre-funded warrants for aggregate gross proceeds of approximately US$100 million, ...
AllPennyStocks.com

Advertisement|Remove ads.